Cardiogenesis Corporation to Report 2009 Fourth Quarter and Full-Year Results on March 3rd
February 23 2010 - 6:30AM
PR Newswire (US)
IRVINE, Calif., Feb. 23 /PRNewswire-FirstCall/ -- Cardiogenesis
Corporation (Pink Sheets: CGCP), announced that the company will
release results for its fourth quarter and full-year ended December
31, 2009 on Wednesday March 3, 2010. The company added that Paul J.
McCormick, its Executive Chairman, and William R. Abbott, its
Senior Vice President and Chief Financial Officer, will host an
investor conference call that day at 5:00 p.m. Eastern time (2:00
p.m. Pacific time) to review the company's financial results and
business outlook. The call is open to all interested investors
through a live audio broadcast via the Internet at
http://www.cardiogenesis.com/. The call also will be available to
investors and analysts by dialing (866) 510-0676 within the U.S.
and Canada and (617) 597-5361 from abroad. The passcode is
35890330. The webcast will be archived on the company's web site
and will be available for playback for seven days beginning shortly
after the live webcast. A telephonic playback of the conference
call will be available beginning at 8:00 p.m. Eastern time on
Wednesday, March 3, 2010, and continue through 8:00 p.m. Eastern
time on Wednesday, March 10, 2010. The replay can be accessed by
calling (888) 286-8010 within the U.S. and Canada and (617)
801-6888 from abroad. The replay passcode is 96086287. About
Cardiogenesis Corporation Cardiogenesis is a medical device company
specializing in the treatment of cardiovascular disease and is a
leader in devices that stimulate cardiac angiogenesis. The
company's market leading Holmium:YAG laser system and disposable
fiber-optic accessories are used to perform a FDA-cleared surgical
procedure known as Transmyocardial Revascularization (TMR) to treat
patients suffering from angina. Surgical products and accessories
for the Cardiogenesis TMR procedure, which are marketed in the U.S.
and around the world, have been shown to reduce angina and improve
the quality of life in patients with coronary artery disease. For
more information on the company and its products, please visit the
Cardiogenesis company website at http://www.cardiogenesis.com/.
DATASOURCE: Cardiogenesis Corporation CONTACT: William R. Abbott,
Senior Vice President and Chief Financial Officer of Cardiogenesis
Corporation, +1-949-420-1800 Web Site:
http://www.cardiogenesis.com/
Copyright